米多司他林
奥佐美星
医学
化疗
诱导化疗
髓性白血病
髓系白血病
内科学
卡奇霉素
肿瘤科
药理学
CD33
干细胞
川地34
遗传学
生物
作者
Christoph Röllig,Christoph Schliemann,Leo Ruhnke,Lars Fransecky,Björn‐Niklas Heydrich,Maher Hanoun,Richard Noppeney,Kerstin Schäfer‐Eckart,Knut Wendelin,Jan‐Henrik Mikesch,Jan Moritz Middeke,Manja Reimann,Frank Fiebig,Sven Zukunft,Martin Wermke,Hubert Serve,Uwe Platzbecker,Carsten Müller‐Tidow,Claudia D. Baldus,Martin Bornhäuser
摘要
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m
科研通智能强力驱动
Strongly Powered by AbleSci AI
丰盛的煎饼
西红柿炒番茄
乐乐乐乐乐乐
加菲丰丰
Hayat
kento
寻道图强
ShowMaker
杳鸢
爱静静
YifanWang
冒险寻羊
lanxinyue
spark810
景辣条
乐乐
大仙
互助遵法尚德
yyymmma
斯文败类
皖公网安备34019202002308
